AI-Powered Cancer Diagnostics Firm Targets $400M IPO
Caris Life Sciences Inc., a developer of artificial-intelligence enhanced cancer diagnostic tests, on Monday launched plans for an estimated $400 million initial public offering, represented by Latham & Watkins LLP and...To view the full article, register now.
Already a subscriber? Click here to view full article